Pell Bio-Med Technology Co., Ltd. (TPE:6949)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
862.00
-17.00 (-1.93%)
Jun 26, 2026, 1:30 PM CST
536.16%
Market Cap 55.85B
Revenue (ttm) 25.85M
Net Income (ttm) -424.75M
Shares Out 64.79M
EPS (ttm) -7.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 146,455
Average Volume 248,504
Open 870.00
Previous Close 879.00
Day's Range 840.00 - 875.00
52-Week Range 133.00 - 968.00
Beta 1.05
RSI 63.53
Earnings Date Aug 6, 2026

About Pell Bio-Med Technology

Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the research, development, manufacturing, and sales of chimeric antigen recombinant T cell (CAR-T), and other related services and products. It offers autologous adipose-derived stem cell (ADSC) products to treat osteoarthritis and cartilage defects in the knee; cytokine-induced Killer cells to treat various tumors; and dendritic cell-activated cytokine-induced killer to treat solid tumors. The company is also involved in the phase 1/2 multicenter study to evaluate the safety a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6949
Full Company Profile

Financial Performance

In 2025, Pell Bio-Med Technology's revenue was 31.42 million, an increase of 60.07% compared to the previous year's 19.63 million. Losses were -423.94 million, 8.87% more than in 2024.

Financial Statements

News

There is no news available yet.